Philips’ Capsule Surveillance secures FDA clearance

USA – The Philips Capsule Surveillance solution has been granted 510(k) market clearance by the United States Food and Drug Administration (FDA), paving the way for widespread deployment across healthcare systems in the United States.

Capable of utilizing streaming data from virtually any connected medical device, the solution aggregates patient data, analyzes it to generate actionable insights and alerts, and sends timely notifications to the patient’s caregivers so that they can intervene before further deterioration occurs.

Amsterdam-based Philips created its Philips Capsule Surveillance solution to aggregate patient data, analyze the data to generate actionable insights and alerts, and send timely notifications to caregivers so they can intervene before any patient deterioration worsens.

In a news release, the company stated that the latest release includes expanded interoperability into hospitals’ existing mobile clinical communication and collaboration tools, as well as electronic intensive care units and virtual care population health management systems.

Enhanced data visibility

According to Philips, this design improves visibility of live streaming data, waveforms, device alarms, and contextual alerts.

Without entering a patient’s room, Philips Capsule Surveillance allows clinicians to view patient data, patient monitor settings, and alarms from multiple device types.

This can help reduce the risk of infection for clinical staff caring for infectious patients, while early detection of deteriorating patient conditions can help avoid complications and escalation, contributing to lower costs of care and more efficient resource use.

The company plans to release the latest version of the Philips Capsule Surveillance in the second quarter of 2022 to limited sites in the U.S.

“This FDA clearance of the latest release of clinical surveillance solution enables more integrated viewing options within EMR and HIT tools through the secure web-based user interface,” Philips GM of Clinical Data Services Elad Benjamin said in a press release.

“Properly implemented clinical surveillance has the potential to significantly improve patient outcomes by helping to avoid deterioration, while also improving the care team experience via clinical decision support and minimizing the burden of false and clinically unactionable alarms.”

The FDA approval of Philips Capsule Surveillance System follows the company’s announcement of a variety of analytics and interoperability offerings at the 2022 HIMSS Global Health Conference and Exhibition.

Last year, the company paid US$635 million for Capsule Technologies in order to improve its cloud-based digital health platform.

Liked this article? Sign up to receive our regular email newsletters, focused on Africa and World’s healthcare industry, directly into your inbox. SUBSCRIBE HERE